Results 1 to 10 of about 830,895 (193)

Histone deacetylase inhibitors [PDF]

Journal of Education, Health and Sport, 2020
The human genome is contained in chromatin, which is a complex macromolecular complex. It is made of DNA, histones and non-histone proteins. The structure of chromatin and the process of its rearrangement regulate the process of transcription, and hence ...
Marzena Baran, Paulina Anna Miziak, Katarzyna Bonio   +2 more
doaj   +2 more sources

Role of histone deacetylase inhibitors in non-neoplastic diseases [PDF]

Heliyon
Background: Epigenetic dysregulation has been implicated in the development and progression of a variety of human diseases, but epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules ...
Chunxiao Zhou, Dengke Zhao, Chunyan Wu, Zhimin Wu, Wen Zhang, Shilv Chen, Xindong Zhao, Shaoling Wu   +7 more
doaj   +2 more sources

Histone deacetylase inhibitors for leukemia treatment: current status and future directions [PDF]

European Journal of Medical Research
Leukemia remains a major therapeutic challenge in clinical oncology. Despite significant advancements in treatment modalities, leukemia remains a significant cause of morbidity and mortality worldwide, as the current conventional therapies are ...
Mohammad-Salar Hosseini, Zohreh Sanaat, Mohammad Amin Akbarzadeh, Yosra Vaez-Gharamaleki, Mahsa Akbarzadeh   +4 more
doaj   +2 more sources

Comprehensive suppression of all apoptosis-induced proliferation pathways as a proposed approach to colorectal cancer prevention and therapy. [PDF]

PLoS ONE, 2014
Mutations in the WNT/beta-catenin pathway are present in the majority of all sporadic colorectal cancers (CRCs), and histone deacetylase inhibitors induce apoptosis in CRC cells with such mutations.
Michael Bordonaro, Eric Drago, Wafa Atamna, Darina L Lazarova   +3 more
doaj   +1 more source

A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma

Frontiers in Oncology, 2023
This review aims to summarize the putative role of histone deacetylases (HDACs) in rhabdomyosarcoma (RMS) and the effects of HDAC inhibitors (HDACi) on RMS by elucidating and highlighting known oncogenic pathways, mechanisms of resistance, and the ...
Omar Selim, Clara Song, Amy Kumar, Rebecca Phelan, Arun Singh, Noah Federman, Noah Federman, Noah Federman   +7 more
doaj   +1 more source

Medicinal chemistry of histone deacetylase inhibitors [PDF]

Arhiv za farmaciju, 2021
Today, we are witnessing an explosion of scientific concepts in cancer chemotherapy. It has been considered for a long time that genetic instability in cancer should be treated with drugs that directly damage the DNA. Understanding the molecular basis of
Ružić Dušan, Đoković Nemanja, Nikolić Katarina, Vujić Zorica   +3 more
doaj   +1 more source

Histone Deacetylase Inhibitors: A Novel Strategy for Neuroprotection and Cardioprotection Following Ischemia/Reperfusion Injury

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Ischemia/reperfusion injury is a complex molecular cascade that causes deleterious cellular damage and organ dysfunction. Stroke, sudden cardiac arrest, and acute myocardial infarction are the most common causes of ischemia/reperfusion injury without ...
Zachary Pickell, Aaron M. Williams, Hasan B. Alam, Cindy H. Hsu   +3 more
doaj   +1 more source

Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas

Haematologica, 2018
Histone deacetylase inhibitors are promising agents for various T-cell lymphomas, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and adult T-cell lymphoma/leukemia. CCR4 is an important therapeutic target molecule because mogamulizumab,
Akihiro Kitadate, Sho Ikeda, Fumito Abe, Naoto Takahashi, Norio Shimizu, Kosei Matsue, Hiroyuki Tagawa   +6 more
doaj   +1 more source

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report

Haematologica, 2009
Histone deacetylase inhibitors are a class of anti-neoplastic agents that induce growth arrest, differentiation, and/or apoptotic cell death of transformed cells in vitro and in vivo.
David Ritchie, Richard L. Piekarz, Piers Blombery, Laszlo J. Karai, Stefania Pittaluga, Elaine S. Jaffe, Mark Raffeld, John E. Janik, H. Miles Prince, Susan E. Bates   +9 more
doaj   +1 more source

Induction of DARPP-32 by brain-derived neurotrophic factor in striatal neurons in vitro is modified by histone deacetylase inhibitors and Nab2. [PDF]

PLoS ONE, 2013
Neurotrophins and modifiers of chromatin acetylation and deacetylation participate in regulation of transcription during neuronal maturation and maintenance.
Samira Chandwani, Serene Keilani, Maitane Ortiz-Virumbrales, Andrika Morant, Steve Bezdecny, Michelle E Ehrlich   +5 more
doaj   +1 more source